Inclusion Criteria:

- Signed Informed Consent Form

- Locally recurrent or metastatic breast cancer

- Receipt of first systemic cytotoxic chemotherapy and/or targeted therapy among those
with HER2-negative disease or first hormone therapy among those with HR-positive
disease for the treatment of locally recurrent or metastatic disease, within 8 weeks
prior to enrollment

Exclusion Criteria

- Any medical condition, including mental illness or substance abuse, deemed by the
investigator to be likely to interfere with a patient's ability to provide informed
consent or comply with the treatment

- Any prior chemotherapy started more than 8 weeks prior to enrollment for the
treatment of locally recurrent or for metastatic breast cancer

- Concurrent participation only in a blinded clinical trial